Önder BİLGE, Rojhat ALTINDAĞ, Erkan BAYSAL, Bernas ALTINTAŞ

Sol Ventrikül Sistolik Fonksiyonu Korunmuş Koroner Arter Hastalarında Koenzim Q10 Düzeyi ile Diyastolik Disfonksiyon İlişkisi

GİRİŞ ve AMAÇ: Bu çalışmanın amacı, sol ventrikül sistolik fonksiyonları korunmuş koroner arter hastalığı (KAH) olan hastalarda, sol ventrikül diyastolik fonksiyonları ile koenzim Q10 seviyesi arasındaki ilişkiyi araştırmaktır. YÖNTEM ve GEREÇLER: Temmuz ve Ekim 2009 tarihleri arasında koroner anjiyografi uygulanan ve anlamlı KAH tanısı koyulan 20 ve 86 yaşları arasındaki 64 hasta çalışmaya dahil edildi. Hastalar, sol ventrikül diyastolik disfonksiyonunun varlığı ve yokluğuna göre iki gruba ayrıldı. BULGULAR: Çalışmaya toplam 64 önemli KAH hastası dahil edildi; Çalışma hastalarının 42’ si(% 65.6) erkek cinsiyette hastalar oluşturdu. Ortalama yaş 60.5 ± 12.1 yıl olarak tespit edildi. Tüm hastalarda ortalama plazma koenzim Q10 düzeyi 1408.2 ± 346.5 μg / L. Gruplar Koenzim Q10 düzeyleri göre karşılaştırıldığında, sol ventrikül diyastolik disfonksiyonu olan grupta Koenzim Q10 düzeyi 1516.0 ± 381.0 μg / L, sol ventrikül diyastolik disfonksiyonu bulunmayan grupta ise 1285.7 ± 472.6 μg / L olarak tespit edildi (p = 0.08). TARTIŞMA ve SONUÇ: Sistolik fonksiyonları korunmuş olan anlamlı KAH varlığında sol ventrikül diyastolik disfonksiyonu ile koenzim Q10 seviyeleri arasında anlamlı bir ilişki gözlenmedi.

The Relationship Between Coenzyme Q10 Level and Diastolic Dysfunction in Coronary Artery Disease Patients with Preserved Left Ventricular Systolic Function

INTRODUCTION: The aim of this study was to investigate therelationship between left ventricular diastolic functions andcoenzyme Q10 levels in coronary artery disease (CAD)patients with preserved left ventricular systolic functions.METHODS: A total of 64 patients aged between 20 and 86years, in whom coronary angiography were performed anddocumented significant CAD, were included in the studybetween July and October 2009. The patients were classifiedinto two groups based on the presence and absence Leftventricular diastolic dysfunction (LVDD).RESULTS: A total of 64 significant CAD patients wereincluded in the study, of whom 42 (65.6%) were male. Themean age was 60.5±12.1 years. The mean plasma coenzymeQ10 level in all patients was 1408.2±346.5 μg/L. The groupswere compared for coenzyme Q10 levels, which were found tobe 1516.0±381.0 μg/L in the presence of LVDD (+) and1285.7±472.6 μg/L in the absence of LVDD group (p =0.08).DISCUSSION and CONCLUSION: A significant relationshipwas not observed between LVDD and coenzyme Q10 levels inthe presence of significant CAD with preserved systolicfunctions.

PDF

___

Othman 1.Pepe S, Marasco SF, Haas SJ, Sheeran FL, Krum H, Rosenfeldt FL. Coenzyme Q 10 in cardiovascular disease. Mitochondrion. 2007 Jun;7 Suppl: S154-67.
Molyneux SL, Florkowski CM, Lever M, George PM. Biological variation of coenzyme Q10. ClinChem 2005;51:455-7.
Turunen M, Olsson J, Dallner G. Metabolism and function of coenzyme Q,Biochimica et BiophysicaActa (BBA) - Biomembranes, Volume 1660, Issue 1-2, January 2004, Pages 171-99.
Crane FL ve ark. Biochemical Functions of Coenzyme Q10, Journal of the American College of Nutrition 2001; 20: 591-8.
Ito H, Nakajima T, Takikawa R, Hamada E, Iguchi M, Sugimoto T et al. Coenzyme Q10 attenuates cyanide activation of the ATP-sensitive K+ channel current in single cardiac myocytes of the guinea-pig. NaunynSchmiedebergs Arch Pharmacol. 1991;344:133-6.
Huynh K, Kiriazis H, Du XJ, Love JE, Jandeleit-Dahm KA, Forbes JM et al.Coenzyme Q10 attenuates diastolic dysfunctions, cardiomyocyte and cardiac fibrosis in the db/db mause model of tpe 2 diabetes. Diabetologia. 2012 May;55:1544-53.
Kumar A, Kaur H, Devi P, Mohan V (2009) Role of coenzyme Q10 (CoQ10) in cardiac disease, hypertension and Meniere-like syndrome. Pharmacol Ther 124:259-68
Langsjoen, P. H., & Folkers, K. (1993). Isolated diastolic dysfunction of the myocardium and its response to CoQ10 treatment. ClinInvestig 71(8 Suppl), S140-4
Langsjoen PH, Langsjoen A, Willis R, Folkers K. Treatment of hypertrophic cardiomyopathy with coenzyme Q10. Mol Aspects Med. 1997;18 Suppl:S145-51.
Rickham PP. Human Experimentation. Code of Ethics of the World Medical Association. Declaration of Helsinki. Br Med J.1964;2:177
Quiñones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA; Doppler Quantification Task Force of the Nomenclature and Standards Committee of theAmerican Society of Echocardiography. Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am SocEchocardiogr. 2002 Feb;15:167-84.
Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr. 2009 Feb;22:107-33.
Van Jaarsveld H, Potgeiter GM, Loschner A. Changes in NADH-coenzyme Q10 reductase (complex I) with autolysis in the rat heart as experimental model. Enzyme. 1986;35:206-14.
Folkers, K, Littarru G. P, Ho L, Runge T. M, Havanonda S, & Cooley D. (1970). Evidence for a deficiency of coenzyme Q10 in human heart disease. Int J VitamNutr Res 40, 380-90.
Mabuchi H, Nohara A, Kobayashi J, Kawashiri MA, Katsuda S, Inazu A et al; Hokuriku Lipid Research Group. Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: a randomized double-blind study. Atherosclerosis. 2007 Dec;195:182-9.
Hughes K, Lee BL, Feng X, Lee J, Ong CN. Coenzyme Q10 and differnces in coronary heart disease risk in Asian Indians and Chinese. Free RadicBiol Med. 2002 Jan 15;32:132-8.
Lagendijk J, Ubbink JB, Vermaak WJ. Measurement of the ratio between the reduced and oxidized forms of coenzyme Q10 in human plasma as a possible marker of oxidative stres. J Lipid Res 1996;37:67–75.
Yamashita S, Yamamoto Y. Simultaneous detection of ubiquinol and ubiquinone in human plasma as a marker of oxidative stres. Anal Biochem 1997;250:66-73.
Lagendijk J, Ubbink JB, Delport R, Vermaak WJ, Human JA. Ubiquinol/ubiquinon ratio as marker of oxidative stres in coronary artery disease. ResCommunMolPatholPharmacol. 1997 Jan;95:11- 20.
Ruiz-Jiménez J, Priego-Capote F, Mata- Granados JM, Quesada JM, Luque de Castro MD. Determination of the ubiquinol-10 (coenzyme Q10) in human serum by liquid chromatography tandem mass spectrometry to evaluate the oxidative stress. J Chromatogr A. 2007 Dec 21;1175:242-8.
Miles MV, Horn PS, Morrison JA, Tang PH, DeGrauw T, Pesce AJ. Plazma CoQ10 refernce intervals, but not redox status, are affected by Gender and race in self-reported healthy adults. ClinChimActa 2003;332:123-32.
Miles MV, Horn PS, Tang PH, Morrison JA, Miles L, DeGrauw T et al. Age-related changes in plasma coenzyme Q10 concentrations and redox state in apparently healhy children and adults. ClinChimActa 2004;347:139-44.
Kumar A, Kaur H & Mohan V (2007). Coenzyme Q10 in isolated diastolic heart failure in hypertrophic cardiomyopathy (HCM). The 5th Conference of the International Coenzyme Q10 Association, Kobe Japan.
Ghirlanda G, Oradei A, Manto A, Lippa S, Uccioli L, Caputo S, et al. (1993). Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double blind, placebocontrolled study. Clin Pharmocol J 33: 226-9.
Silver MA &Langsjoen PH (2003). Statin cardiomyopathy: a potential role for coenzyme Q10 therapy for statin induced changes in diastolic LV performance: description of a clinical protocol. Bio factors 18(1–4), 125-7.
Silver MA, Langsjoen PH, Szabo S, Patil H, Zelinger A. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. Am J Cardiol. 2004 Nov 15;94:1306-10.
Chew GT, Watts GF, Davis TM, Stuckey BG, Beilin LJ, Thompson PL et al. Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetics subjects with left ventricular diastolic dysfunctions. Diabetes Care. 2008 Aug;31:1502-9.